These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 1751146)
1. Effect of recombinant human erythropoietin on vascular access. Dy GR; Bloom EJ; Ijelu GK; Merritts GW; Kramer MS; Raja RM ASAIO Trans; 1991; 37(3):M274-5. PubMed ID: 1751146 [TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin does not increase clotting in vascular accesses. Besarab A; Medina F; Musial E; Picarello N; Michael H ASAIO Trans; 1990; 36(3):M749-53. PubMed ID: 2252802 [TBL] [Abstract][Full Text] [Related]
3. Access thrombosis, hospitalization, and hematocrit level in hemodialysis patients. Heard KA; Russell TA Nephrol Nurs J; 2000 Dec; 27(6):607-11. PubMed ID: 16649341 [TBL] [Abstract][Full Text] [Related]
4. A possible side-effect of human erythropoietin therapy: thrombosis of peripheral arterial reconstruction. Mingoli A; Sapienza P; Puggioni A; Modini C; Cavallaro A Eur J Vasc Endovasc Surg; 1999 Sep; 18(3):273-4. PubMed ID: 10479636 [No Abstract] [Full Text] [Related]
5. Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. Martino MA; Vogel KM; O'Brien SP; Kerstein MD J Am Coll Surg; 1998 Dec; 187(6):616-9. PubMed ID: 9849735 [TBL] [Abstract][Full Text] [Related]
6. Vascular access thrombosis during recombinant human erythropoietin therapy. Tang IY; Vrahnos D; Valaitis D; Lau AH ASAIO J; 1992; 38(3):M528-31. PubMed ID: 1457917 [TBL] [Abstract][Full Text] [Related]
7. Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. Song IS; Yang WS; Kim SB; Lee JH; Kwon TW; Park JS Nephrol Dial Transplant; 1999 Jan; 14(1):137-41. PubMed ID: 10052493 [TBL] [Abstract][Full Text] [Related]
8. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
9. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates? Standage BA; Schuman ES; Ackerman D; Gross GF; Ragsdale JW Am J Surg; 1993 May; 165(5):650-4. PubMed ID: 8488954 [TBL] [Abstract][Full Text] [Related]
10. Low dose streptokinase therapy for thrombosed arteriovenous fistulas. Klimas VA; Denny KM; Paganini EP; Graor RA; Nakamoto S; Risius B; Young J Trans Am Soc Artif Intern Organs; 1984; 30():511-3. PubMed ID: 6533933 [No Abstract] [Full Text] [Related]
11. Clinical effects of recombinant human erythropoietin in hemodialysis patients. Results of the "Abruzzo" Multicenter Trial. Di Paolo B; Di Liberato L; Summa R; Catucci G; Del Rosso G; Muscianese P; Albertazzi A ASAIO Trans; 1991; 37(3):M380-1. PubMed ID: 1751197 [TBL] [Abstract][Full Text] [Related]
12. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. Duff DR; Golper TA; Sloan RS; Brier ME; Aronoff GR Am J Kidney Dis; 1991 Jul; 18(1):60-4. PubMed ID: 2063856 [TBL] [Abstract][Full Text] [Related]
13. [The observation of therapy of anemia in chronic renal failure with recombinant human erythropoietin]. Jiang Y; Liu P; Wang EJ Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):80-2. PubMed ID: 8070295 [TBL] [Abstract][Full Text] [Related]
14. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. Besarab A; Golper TA ASAIO Trans; 1991; 37(3):M395-6. PubMed ID: 1751205 [TBL] [Abstract][Full Text] [Related]
15. [Noninvasive assessment of Cimino-Brescia fistulas and polytetrafluoroethylene shunts with duplex sonography]. Kathrein H; König P; Dittrich P; Judmaier G Vasa Suppl; 1988; 26():39-41. PubMed ID: 3059546 [No Abstract] [Full Text] [Related]
16. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Grandaliano G; Teutonico A; Allegretti A; Losappio R; Mancini A; Gesualdo L; Schena FP; Pertosa G Kidney Int; 2003 Aug; 64(2):715-9. PubMed ID: 12846770 [TBL] [Abstract][Full Text] [Related]
17. [Analysis of the survival of permanent vascular access ports]. Rodríguez JA; Ferrer E; Olmos A; Codina S; Borrellas J; Piera L Nefrologia; 2001; 21(3):260-73. PubMed ID: 11471307 [TBL] [Abstract][Full Text] [Related]
18. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters]. Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909 [TBL] [Abstract][Full Text] [Related]
19. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin]. Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900 [TBL] [Abstract][Full Text] [Related]
20. Intradialytic serial vascular access flow measurements. Rehman SU; Pupim LB; Shyr Y; Hakim R; Ikizler TA Am J Kidney Dis; 1999 Sep; 34(3):471-7. PubMed ID: 10469857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]